VolitionRX Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.3M
- Price
- $0.4169
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.74%
- Volume
- 545.8K
About
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Quick stats
Shares outstanding12.8M
Computed float11.1M
Float / shares86.6%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000093314
Websitehttps://volition.com
AI Summary
AI-generated1/41
standardbullishearnings
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
VolitionRx reported second quarter revenue of approximately $0.4 million, flat year-over-year, while first-half revenue grew 112% to $1.4 million.
Operating expenses fell 32% in the quarter, driving a 34% reduction in operating loss to $4.2 million, as the company focuses on cost discipline.
Management is actively negotiating licensing deals with over a dozen diagnostic companies targeting a $27 billion total addressable market and secured $5.3 million in financing proceeds during the quarter.
Red flags
- Q2 revenue was flat year-over-year
- Operating loss of $4.2 million and net cash burn of $5.2 million for the quarter